Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

AstraZeneca - Key questions on PARP inhibitors in ovarian cancer: Experts evaluate the latest evidence

Global experience using PARP inhibitors in treatment of ovarian cancer

Date

25 Jun 2021

Session

AstraZeneca - Key questions on PARP inhibitors in ovarian cancer: Experts evaluate the latest evidence

Presenters

Jonathan Ledermann

Authors

J. Ledermann

Author affiliations

  • UCL Cancer Institute, London/GB
More

Resources

Login to access the resources on OncologyPRO.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings